ALLO

Allogene Therapeutics, Inc. Common Stock

1.67

USD

-0.04

-2.34%

Sep 23, 15:42 UTC -4

Closed

After-Market

1.70

+0.03

+1.56%

Allogene Therapeutics, Inc. Common Stock Profile

About

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.?

Info & Links

CEO

David Chang

Headquarters

210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

152

Allogene Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

585.95M

Enterprise Value

547.33M

Enterprise Value/EBITDA(ttm)

-3.17

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

Price to Book(mrq)

1.34

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

Profit Margin(ttm)

-229.94%

Return on Equity(ttm)

-50.04%

Return on Invested Capital(ttm)

-51.46%

Return on Assets(ttm)

-36.74%

Income Statement

Revenue(ttm)

4.64M

Revenue Per Share(ttm)

0.01

Gross Profit(ttm)

4.64M

EBITDA(ttm)³

-172.59M

Net Income Available to Common(ttm)

-165.49M

Diluted EPS(ttm)

-0.67

Share Statistics

Beta (5Y Monthly)

0.47

52-Week Change

42.74%

S&P 500 52-Week Change

17.10%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

345.49M

Dividend Yield

0.00%

Float⁴

299.89M

% Held by Insiders

13.20%

% Held by Institutions

83.63%

Balance Sheet

Total Cash(mrq)

332.60M

Total Cash Per Share(mrq)

0.96

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

10.72%

Quick Ratio(mrq)

10.72%

Book Value Per Share(mrq)

1.26

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.14

Free Cash Flow(ytd)

-45.07M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.